Sokun Bhatti, MD
Allergy & Immunology · Newark, DENPI 1225249113
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 280 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,012 and has fallen 69.1% since, to $313 in 2025.
Across 280 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$713
- Takeda Pharmaceuticals U.S.A., Inc.$673
- Pfizer$551
- AstraZeneca$456
- AbbVie$305
- Regeneron Healthcare Solutions, Inc.$294
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,56097%
- Education$1443%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 49 | $713 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $673 |
| Pfizer | 52 | $551 |
| AstraZeneca | 26 | $456 |
| AbbVie | 17 | $305 |
| Regeneron Healthcare Solutions, Inc. | 13 | $294 |
| Biocryst US Sales Co., LLC | 9 | $254 |
| CSL Behring | 14 | $231 |
| Novartis | 10 | $185 |
| Sanofi | 7 | $175 |
| Covis Pharma GmbH | 6 | $109 |
| Bio Products Laboratory USA, Inc. | 7 | $106 |
| Genentech USA, Inc. | 5 | $90 |
| Kaleo, Inc. | 5 | $74 |
| Sanofi-aventis U.S. LLC | 1 | $64 |
| Teva Pharmaceuticals USA, Inc. | 4 | $64 |
| Amgen | 3 | $62 |
| Pharming Healthcare, Inc. | 2 | $44 |
| Grifols USA, LLC | 2 | $41 |
| Optinose US, Inc. | 2 | $36 |
| Incyte Corporation | 1 | $28 |
| Boehringer Ingelheim | 1 | $20 |
| LEO Pharma Inc. | 1 | $20 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
| Greer Laboratories, Inc. | 1 | $17 |
| Circassia Inc. | 1 | $17 |
| Octapharma USA, Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Alk-abello, Inc | 1 | $13 |
| Biocryst Pharmaceuticals, Inc. | 1 | $12 |
How this compares
Too few allergy & immunology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HyqviaIgg/Hyaluronidase,recombinant | 31 | $130,432 |
| Dupixent PenDupilumab | 33 | $124,048 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $109,017 |
| Breo ElliptaFluticasone/Vilanterol | 106 | $81,778 |
| Dupixent SyringeDupilumab | 14 | $52,018 |
| Arnuity ElliptaFluticasone Furoate | 55 | $27,153 |
| Spiriva RespimatTiotropium Bromide | 16 | $19,287 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $18,145 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $12,995 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $12,921 |
| XhanceFluticasone Propionate | 15 | $11,560 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $11,055 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $7,690 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $6,891 |
| Epinephrine | 35 | $6,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $713 | $230,869267 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $673 | $130,43231 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $456 | $35,57954 claims |
| Boehringer IngelheimSpiriva Respimat | $20 | $19,28716 claims |
| Optinose US, Inc.Xhance | $36 | $11,56015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Delawareon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Newark
- Junfang JiaoNewark$20K
- Muhammad KhalidNewark$3K
- David WienWilmington$17K
- Gregory MarcotteWilmington$17K
- Michael WydilaWilmington$7K
- Michelle SquadritoWilmington$5K
- Lyvia LeighLewes$4K
- Richard KimWilmington$4K
- Isma ShahWilmington$3K
- Amulya AmirneniLewes$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.